eversea

Eversea Confirms Launch of the World's First Organic Omega-3 DHA Supplement Across USA

(TheNewswire)



SOLARVEST BIOENERGY INC. (TSXV:SVS) ("Solarvest" or the " Company " ), is pleased to provide an update to the December 21, 2020 press release of its highly-bioavailable Organic Omega-3 Children's Supplement. The product, marketed under the Company's Eversea brand, is the world's first and only Organic Omega-3 children's fruit drop. Eversea seeks to benefit from the extensive and growing market demand for organic, vegetarian and vegan diets.  Eversea's organically certified supplement holds a competitive advantage with several differentiating factors focused on sustainability, environmental conservation, bioavailability and purity, establishing a new market segment for Organic Omega-3 nutraceuticals

The Eversea Organic Omega-3 Fruit Drop is now available to health conscientious customers throughout the USA directly from its e-commerce web site at https://eversea.ca/ and Amazon.  This initial Children's Omega-3 supplement, being Non-GMO, USDA Organic and EU Organic Certified is a unique and a premium entry product that is positioned to take advantage of the significant and growing demand for plant-based products.  Eversea's Organic Omega-3 is over 80% dried fruit, contains no added sugar, tests free from all common allergens and contains the Company's patented and highly bioavailable O rganic Omega-3 DHA powder.

"This Organic Omega-3 Children's Fruit Drop will appeal to customers looking for a sustainably sourced and organic product, without any nutrient-degrading industrial processing or chemicals. This process yields a pure, whole food Omega-3 with higher bioavailability than flaxseed or hemp which only contain ALA Omega-3. Parents can see a clean ingredient label and feel good about feeding their children a wholesome and healthy supplement," said Gerri Greenham, President and CEO of Solarvest.  He continued," Our Omega-3 is truly sustainable and produced using organic strains of algae.  Eversea specifically set out to reduce the pressure on marine species for harvesting Omega-3 and beneficially this process also ensures that our Organic ingredient is free from any contaminants which may be present in our oceans today."

The Company further reports that a second product run with its German-based organically certified manufacturer has now successfully concluded. Beyond the Company's intent to supplement inventory levels, this second Organic DHA ingredient batch will be offered to interested parties both inside and outside North America who have already shown interest in the Organic Omega-3 products. In addition to Company-driven product alternatives, Eversea is engaged to advance the development of a second adolescent offering to complement its Natural Fruit Drop. This product is anticipated to provide organic oriented retailers with house branded products using Eversea's  Omega-3 DHA active ingredient to provide a patented competitive advantage.

The Company is reaching out to larger established distributors to secure a distribution pipeline for its Organic Omega-3 products under the Company's "Eversea Brand" or other "Home Brands" to achieve scalability and allow the Company to readily market their Organic Omega-3 products.

Corporate

The company also announces that Greg Drohan (see press release dated January 5, 2021) has officially joined the Board of Directors and that Ken Cawkell has resigned from the Board of Directors after many years of valuable service. We thank him for his invaluable contributions and continued support as he will remain on as the corporate lawyer for the Company.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less

Latest Press Releases

Related News

×